Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
1(33.3%)
Phase 3
1(33.3%)
Phase 2
1(33.3%)
3Total
N/A(1)
Phase 3(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04752228Not ApplicableUnknown

Adverse Childhood Experiences in Patients With Coronary Artery Disease Pilot

Role: collaborator

NCT04435184Phase 2Completed

Crizanlizumab for Treating COVID-19 Vasculopathy

Role: collaborator

NCT00821717Phase 3Terminated

EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure

Role: collaborator

All 3 trials loaded